A-582941
A-582941 is a selective, orally active, blood-brain barrier-permeable α7 nAChR agonist, with Ki values of 10.8 nM and 17 nM in rat brain and human frontal cortex, respectively. A-582941 exhibits agonistic activity at 5-HT3 receptors, with a Ki of 150 nM. A-582941 triggers phosphorylation of ERK1/2 and CREB, inhibits GSK-3β via Ser-9 phosphorylation, increases acetylcholine release, induces the expression of Arc and c-Fos, activates brain regions associated with working memory and attention, and reduces cell death caused by nerve growth factor (NGF) deprivation. A-582941 is applicable for the research of Alzheimer's disease and schizophrenia.
For research use only. We do not sell to patients.
- CAS No.: 848591-89-9
- Formula: C17H20N4
- Molecular Weight:280.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All 5-HT Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
5-HT3 Receptor 150 nM (Ki) |
In Vitro
A-582941 binds with high affinity to α7 nAChRs in rat brain (Ki = 10.8 nM) and human frontal cortex (Ki = 17 nM) membranes, with slightly lower affinity for antagonist-labeled α7 nAChRs (Ki = 88 nM) in rat brain[1].
A-582941 acts as a partial agonist at recombinant human α7 nAChRs in Xenopus oocytes, with an EC50 of 4260 nM and 52% efficacy relative to acetylcholine[1].
A-582941 acts as a partial agonist at recombinant rat α7 nAChRs in Xenopus oocytes, with an EC50 of 2450 nM and 60% efficacy relative to acetylcholine[1].
A-582941 (3 μM PNU-120596 pre-incubated prior to treatment) exhibits increased potency (EC50 = 580 nM) and efficacy (207% relative to acetylcholine) at recombinant human α7 nAChRs in Xenopus oocytes[1].
A-582941 increases ERK1/2 phosphorylation in α7 nAChR-expressing PC12 cells with an EC50 of 95 nM, an effect mediated by α7 nAChRs[1].
A-582941 (0.1-100 μM) protects PC12 cells from NGF withdrawal-induced cell death[1].
A-582941 (100 nM-10,000 nM; 9 days) does not induce proliferation in cultured human keratinocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Cultured human keratinocytes
-
Concentration:100 nM, 10,000 nM
-
Incubation Time:9 days, with medium refreshed every 3-4 days
-
Result:Produced no detectable proliferation under conditions where serum/growth factor supplements evoked significant proliferative events.
Parmacokinetics
| Species | Dose | Route | T1/2 | Vss | CLplasma | Cmax | Bioavailability |
|---|---|---|---|---|---|---|---|
| Mice[1] | 1.0 μmol/Kg | i.v. | 1.4 h | 11.4 L/kg | 7.9 L/h/kg | / | / |
| Mice[1] | 1.0 μmol/Kg | p.o. | / | / | / | 18 ng/mL | ~100 % |
| Rat[1] | 6.2 μmol/Kg | i.v. | 1.5 h | 9.2 L/kg | 4.7 L/h/kg | / | / |
| Rat[1] | 6.2 μmol/Kg | p.o. | / | / | / | 114 ng/mL | 90 % |
| Dog[1] | 0.5 μmol/Kg | i.v. | 1.4 h | 7.9 L/kg | 5.3 L/h/kg | / | / |
| Dog[1] | 3.0 μmol/Kg | p.o. | / | / | / | 79 ng/mL | 22 % |
| Monkey[1] | 0.5 μmol/Kg | i.v. | 2.0 h | 3.9 L/kg | 1.6 L/h/kg | / | / |
| Monkey[1] | 3.0 μmol/Kg | p.o. | / | / | / | 39 ng/mL | 50 % |
In Vivo
A-582941 (0.01-1.00 μmol/kg; i.p.) improves memory consolidation in mice, with full efficacy achieved at 0.1 μmol/kg (i.p.)[1].
A-582941 (0.1-1.0 μmol/kg; i.p.) dose-dependently increases Ser-9 GSK-3β phosphorylation in the mouse cingulate cortex[1].
A-582941 (0.1-1.0 μmol/kg; i.p.) improves short-term recognition memory in rats, with full efficacy achieved at 0.1 μmol/kg (i.p.)[1].
A-582941 (3 μmol/kg; i.p.; once daily; 3 consecutive days) moderately increases medial prefrontal cortex acetylcholine release in freely moving rats[1].
A-582941 (1.8 μmol/kg/day; s.c.; continuous infusion; 7 days) maintains efficacy in improving rat short-term recognition memory[1].
A-582941 (0.003-0.100 μmol/kg; i.m.) improves working memory in young Rhesus monkeys, with full efficacy achieved at 0.01 μmol/kg (i.m.)[1].
A-582941 (10 μmol/kg; i.p.) reverses MLA (HY-N2332)-induced sensory gating deficit in rats[1].
A-582941 (3-10 μmol/kg; i.p.) improves genetic sensory gating deficit in DBA/2J mice, with efficacy retained after 5 consecutive days of 3 μmol/kg (i.p.) dosing[1].
A-582941 (0.1-1.0 μmol/kg; s.c.) modestly improves response inhibition/impulsivity in spontaneously hypertensive rat pups[1].
A-582941 (0.1-10 mg/kg; s.c.; single dose) induces dose-dependent increases in Arc and c-Fos mRNA and protein expression in limbic forebrain regions of juvenile male Wistar rats, with maximal effects at 10 mg/kg and greater responsiveness observed in juvenile compared to adult rats[2].
A-582941 (0.1-10 mg/kg; s.c.; single dose) increases Arc and c-Fos immunoreactive cell counts in limbic forebrain regions of adult male Wistar rats at 10 mg/kg, but does not induce measurable increases in Arc or c-Fos mRNA expression in any examined region[2].
A-582941 (1.14-38 μg/kg; i.m.; single dose) significantly improves delayed matching-to-sample task accuracy in young adult Rhesus monkeys, with a 22.2% increase in long delay trial accuracy (twice the magnitude of improvement in short delay trials) that is not sustained 24 hours after dosing[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified strain[1]
-
Dosage:1.8 μmol/kg/day
-
Administration:s.c.; continuous infusion; 7 days
-
Result:Maintained efficacy in the social recognition test, as reflected by a reduced ratio of investigative behavior during the second session (T2) compared to the first session (T1).
Reached a mean steady-state plasma concentration of 3.1 ± 0.3 ng/mL (11 nM).
-
Animal Model:DBA/2J[1]
-
Dosage:3 μmol/kg (acute; 5-day repeated dosing); 10 μmol/kg (acute)
-
Administration:i.p.; acute; once daily; 5 consecutive days
-
Result:Significantly improved sensory gating in acutely treated mice.
Retained efficacy after 5 consecutive days of dosing with 3 μmol/kg (i.p.).
Reached an average plasma concentration of 44 ng/mL (157 nM) after 5 days of repeated dosing.
-
Animal Model:Wistar rats (adult, male, approximately 55 days, 210-230 g)[2]
-
Dosage:0.1, 0.3, 1, 3 and 10 mg/kg
-
Administration:s.c.; single dose
-
Result:Did not induce significant increases in Arc or c-Fos mRNA expression in any brain region examined (mPFC, VO/LO cortex, hippocampus).
Increased Arc immunoreactive cell counts at 10 mg/kg in the mPFC (262% increase vs controls), VO/LO cortex (233% increase vs controls), ACCshell (851% increase vs controls), and dmSTR (419% increase vs controls); no significant effect was seen in the ACCcore or dlSTR.
Increased c-Fos immunoreactive cell counts at 10 mg/kg in the mPFC (97% increase vs controls), VO/LO cortex (115% increase vs controls), and ACCshell (169% increase vs controls); no significant effect was seen in the ACCcore, dmSTR, or dlSTR.
-
Animal Model:Macaca mulatta (male, 9-18 years old, 7.2-11.8 kg)[3]
-
Dosage:1.14 μg/kg; 3.8 μg/kg; 11.4 μg/kg; 38 μg/kg
-
Administration:i.m.; single dose
-
Result:Significantly improved delayed matching-to-sample (DMTS) task accuracies relative to vehicle controls.
Produced a significant increase in short delay trial accuracy at 11.4 μg/kg dose.
Produced significant increases in long delay trial accuracy at 1.14 μg/kg, 3.8 μg/kg, and 11.4 μg/kg doses.
Increased long delay trial accuracy by 22.2% above control, approximately twice the 11.3% increase observed in short delay trials.
Showed a non-significant trend toward improved accuracy at 38 μg/kg dose.
Produced no statistically significant improvement in task accuracies during sessions initiated 24 hours after dosing, despite mean long delay accuracies remaining above vehicle levels.
Produced no significant effect on sample or choice task latencies.
Chemical Information
-
CAS No. 848591-89-9
-
Molecular Weight 280.38
-
Formula C17H20N4
-
SMILES
N=1N=C(C=CC1C=2C=CC=CC2)N3CC4CN(C)CC4C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
PC12 NGF-Induced Neuronal Differentiation Culture
PC12 cells are a rat adrenal pheochromocytoma clonal line that responds to NGF by stopping proliferation and extending branching neurite-like processes; after longer NGF exposure, cells develop long processes and neuronal-like ultrastructural and functional features. NGF-induced differentiation is read out mainly by neurite outgrowth, reduced proliferation, microtubule assembly, and neuronal differentiation-associated proteins such as MAPs, tau, GAP-43, and synapsin-1.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
PC12 NGF-induced neuronal-like differentiation
PC12 cells are a rat adrenal pheochromocytoma-derived clonal cell line that responds to nerve growth factor by stopping proliferation and extending neurites, producing a sympathetic neuron-like phenotype used to study neuronal differentiation and neurite outgrowth. NGF acts through TrkA-dependent signaling, and neurite outgrowth is associated with ERK/Akt signaling, microtubule organization, neuronal-marker expression, and increased electrophysiological neuronal features such as sodium-channel density. The main assay readout is morphological differentiation, usually measured as the percentage of neurite-bearing cells, neurite length, neurite number, or total neurite length per cell. Additional readouts include GAP-43, tyrosine hydroxylase, βIII-tubulin, neurofilament, synapsin I, synaptophysin, ERK phosphorylation, Akt phosphorylation, and sodium-channel current density.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
[1]. Tietje KR, et al. Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther. 2008;14(1):65-82. [Content Brief]
[2]. Thomsen MS, et al. The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: Differential effects in the juvenile and adult rat. Neuroscience. 2008;154(2):741-753. [Content Brief]
[3]. Buccafusco JJ, et al. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol. 2007;74(8):1202-1211. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)